Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908048 · ClinicalTrials.gov registry record
Extracellular RNA Markers of Liver Disease and Cancer
A clinical trial of Hepatocellular Carcinoma and Cirrhosis, sponsored by Mayo Clinic.
- Active
- Registry status
- 1,810
- Enrollment target
- 4
- Study locations
NCT02908048: Active study of Hepatocellular Carcinoma and Cirrhosis, sponsored by Mayo Clinic.
NCT02908048 is a study of Hepatocellular Carcinoma and Cirrhosis that is active but no longer recruiting, run by Mayo Clinic. The registered enrollment target is 1,810 participants, above the 245-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (639% higher). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02908048, a study of Hepatocellular Carcinoma and Cirrhosis, is active but no longer recruiting, sponsored by Mayo Clinic.
- ACTIVE NOT RECRUITING
- Registry status
- 1,810 participants
- Enrollment target
- 4
- Study locations
Study Summary
The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery
Primary Outcome
The exRNA biomarker levels in the HCC and biliary tract cancer groups will be evaluated and compared to the exRNA biomarker levels present in the other groups, cirrhosis and chronic liver disease. Statistical analysis will be used to evaluate the sensitivity and specificity of these markers for the diagnosis of cancers based on findings of liver mass, imaging characteristics, size, and extent of viable tumor on imaging, or on elevated levels of tumor markers such as alpha-fetoprotein.
Conditions Studied
Interventions
- OTHER Blood samples
Study Locations (4)
Florida
- Mayo Clinic Florida - Jacksonville
Illinois
- The University of Chicago Medical Center - Chicago
Minnesota
- Mayo Clinic - Rochester
Virginia
- McGuire VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,810 participants |
| Start Date | 2014-07 |
| Est. Completion | 2026-07 |
What the registry record for NCT02908048 still lists
NCT02908048 is an observational study that tracks outcomes without assigning an intervention. Its 1,810 participants enrollment target places it among the larger protocols in the corpus, above the 245-participant average among 145 other Hepatocellular Carcinoma trials with a reported enrollment target (639% higher).
The record links to 4 conditions, with Hepatocellular Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Blood samples is the first listed.
NCT02908048 reports a single indexed study location in Florida, Illinois, Minnesota.
Frequently Asked Questions
What is clinical trial NCT02908048 about?
NCT02908048 is a clinical study titled "Extracellular RNA Markers of Liver Disease and Cancer". The study will examine and evaluate the use of extracellular RNA in blood as markers for the diagnosis of liver disease or cancer, and as markers for prediction of response to treatment or recurrence of cancer after surgery
What is the current status of trial NCT02908048?
This trial is currently active not recruiting. The enrollment target is 1,810 participants. The study started on 2014-07. Estimated completion is 2026-07.
What conditions does trial NCT02908048 study?
This clinical trial studies the following conditions: Hepatocellular Carcinoma, Cirrhosis, Biliary Tract Cancer, Liver Diseases.
What interventions are being tested in trial NCT02908048?
The interventions under investigation include: Blood samples (OTHER).
Who is sponsoring clinical trial NCT02908048?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02908048 being conducted?
This trial has 4 study locations across Florida, Illinois, Minnesota, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02908048's enrollment target sits among peer trials
1,810 2nd of 145 the highest of 145 other Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Molecular Basis of Pediatric Liver Cancer
RECRUITING
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
RECRUITING · Phase 1
-
Targeted Navigation in Hepatocellular Carcinoma (HCC)
RECRUITING · NA
-
Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05897788 · 1,808 participants · NA
Text-Messaging Telehealth and Contingency Management for Opioid Use Disorder Treatment Engagement
- NCT05935007 · 1,805 participants
Aveir DR Real-World Evidence Post-Approval Study
- NCT03630055 · 1,800 participants · Phase 3
Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion
- NCT04475640 · 1,800 participants · NA
Cancer Genetic Testing in Ethnic Populations
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia